ASH 2016 – CLL

Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

ASH 2016 – CLL

The most important positive prognostic factor for 2-year nonrelapse mortality in chronic lymphocytic leukemia (CLL) patients following allogeneic hematopoietic stem-cell transplantation (alloSCT) is the donor HLA match. AlloSCT still remains a valid option for younger, high cytogenetic risk, refractory/relapsed CLL patients with an HLA-allele well-matched donor. Read More ›

5-Year Ibrutinib Therapy in Treatment-Naïve Patients with Relapsed or Refractory CLL or SLL

ASH 2016 – CLL

After 5 years of follow-up, single-agent ibrutinib continues to show durable responses in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, including those with del17p, del11q, or unmutated IGVH. Read More ›

Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL

ASH 2016 – CLL

With a median time on study of 28.6 months, ibrutinib demonstrated an 88% reduction in risk of progression or death in an elderly chronic lymphocytic leukemia/small lymphocytic leukemia patient population, with treatment-limiting adverse events decreasing in frequency with longer follow-up. Read More ›

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

ASH 2016 – CLL

The combination of nivolumab and ibrutinib has activity in patients with relapsed, refractory chronic lymphocytic leukemia (CLL) and Richter transformation. Read More ›

Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

ASH 2016 – CLL

Progression-free survival for treatment-naive ibrutinib-treated chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) patients was similar regardless of age subgroup, whereas it was shorter for chlorambucil-treated patients aged ≥75 years compared with those aged 65 to Read More ›

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

ASH 2016 – CLL

In pooled data from 3 randomized studies, the benefit of ibrutinib on progression-free and overall survival is most marked in patients with CLL/SLL with del11q, which is not the case with ofatumumab, chlorambucil, or bendamustine/rituximab. Read More ›

Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients

ASH 2016 – CLL

Ibrutinib plus fludarabine/cyclophosphamide/rituximab (FCR) induces deep responses in previously untreated young patients with chronic lymphocytic leukemia (CLL), with 39% of evaluable patients achieving complete response with bone marrow minimal residual disease negativity (BM MRD-neg) and 89% achieving BM MRD-neg, significantly higher than the 20% rate seen historically with FCR alone. Read More ›

Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center

ASH 2016 – CLL

In a single-center study, atrial fibrillation events in patients being treated with ibrutinib were generally manageable and, in the majority of cases, did not result in drug discontinuation. Read More ›

Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification

ASH 2016 – CLL

Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab is associated with low toxicity, a high overall response rate and durable progression-free survival, especially in patients with a mutated IGHV profile and not carrying del17p and del11q. In this low-risk subset of unfit patients, this combination could represent the optimal therapeutic option taking into consideration safety, efficacy, and cost. Read More ›

Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

ASH 2016 – CLL

Ibrutinib enhances intrinsic JCAR017 activity and may improve outcomes in chronic lymphocytic leukemia patients treated with anti-CD19 CAR T therapy, irrespective of Bruton tyrosine kinase mutational status. Read More ›

ASH 2016 – CLL

Page 1 of 2